LGALS3 expression is increased in essential thrombocythemia (ET) leucocytes when compared with polycythemia vera (PV) (p=0.002), primary myelofibrosis (PMF) (p<0.0001) and control leucocytes (p<0.0001) (A). Although there is no difference between PMF leucocytes and control, LGALS3 is highly expressed in negative JAK2 V617F mutation leucocytes from patients with PMF (p=0.013) (B). Interestingly, there was no significant difference in LGALS3 expression between negative or positive for JAK2 V617F mutation leucocytes (p=0.2939) from patients with ET (C). LGALS3 is overexpressed in SET-2 cells treated with JAK inhibitor (D). Patients with ET present high concentration of galectin-3 in plasma when compared with controls (p=0.0168) (E). Significant p values are shown. Otherwise, p>0.05. Horizontal bars show the median 2-ΔΔCt for each group and vertical bars represent the minimum and maximum values.